May 4, 2020 / 12:59 PM / 22 days ago

BRIEF-Allakos Announces Positive Interim Results From An Open-Label Extension Study Of Antolimab

May 4 (Reuters) - Allakos Inc:

* ALLAKOS ANNOUNCES POSITIVE INTERIM RESULTS FROM AN OPEN-LABEL EXTENSION STUDY OF ANTOLIMAB (AK002) IN PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS

* ALLAKOS INC - ANTOLIMAB TREATMENT PROVIDED DURABLE SYMPTOM IMPROVEMENT AND BLOOD AND TISSUE EOSINOPHIL DEPLETION

* ALLAKOS - AS OF APRIL 28, 2020, 35 PATIENTS COMPLETED AT LEAST 52 WEEKS OF ANTOLIMAB TREATMENT

* ALLAKOS - 12 PATIENTS DISCONTINUED ANTOLIMAB TREATMENT PRIOR TO REACHING 52 WEEKS OF TREATMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below